Group 1 - The core point of the news is that Hu Zhengguo, an executive director of Basetone Pharmaceuticals-B (02616.HK), reduced his shareholding by selling 223,000 shares at an average price of HKD 12.007 per share, amounting to approximately HKD 2.678 million [1][2]. - After the sale, Hu Zhengguo's total shareholding decreased to 2.471 million shares, resulting in a reduction of his ownership percentage from 0.18% to 0.17% [1][2].

Group 1 - The core point of the news is that Hu Zhengguo, an executive director of Basestone Pharmaceuticals-B (02616.HK), reduced his shareholding by selling 223,000 shares at an average price of HKD 12.007 per share, totaling approximately HKD 2.678 million [1] - After the sale, Hu Zhengguo's total shareholding decreased to 2.471 million shares, resulting in a reduction of his ownership percentage from 0.18% to 0.17% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 基石藥業 | | | | | | 呈交日期: | 2025年9月4日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 02616 | 說明 | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | --- | --- | --- | --- | --- | --- | | 上月底結存 | 2,000,000,000 | USD | 0.0001 | USD | 200,000 | | 增加 / 減少 (-) | 0 | | | USD | 0 | | 本月底結存 | 2,000,000,000 | USD | 0.0 ...

Core Viewpoint - 基石药业-B (02616.HK) announced the granting of stock options and restricted share units to employees as part of its employee stock ownership plan and restricted share award plan following its initial public offering [1] Group 1 - The company granted a total of 4.8 million stock options to 5 option grantees, with an exercise price of HKD 10.00 per share [1] - Additionally, the company awarded a total of 1.93 million restricted share units to 5 restricted share unit grantees [1]

Group 1 - The company, Basestone Pharmaceuticals-B (02616), announced the grant of a total of 4.8 million stock options to 5 option grantees for the subscription of 4.8 million shares as part of its employee shareholding plan post-initial public offering [1] - Additionally, the company granted a total of 1.93 million restricted share units to 5 restricted share unit grantees under its post-initial public offering restricted share award plan, subject to acceptance by the grantees [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CStone Pharmaceuticals 基石藥業 （於開曼群島註冊成立的有限公司） （股份代號：2616） 本公告乃根據上市規則第17.06A、17.06B及17.06C條刊發。董事會謹此宣佈， 於二零二五年八月二十七日，本公司已(i)根據首次公開發售後僱員持股計劃向5 名購股權承授人授出合共4,800,000份購股權以認購合共4,800,000股股份；及(ii) 根據首次公開發售後受限制股份獎勵計劃向5名受限制股份單位承授人授出合共 1,930,000份受限制股份單位，惟須經承授人接納作實。 I. 根據首次公開發售後僱員持股計劃授出購股權 於二零二五年八月二十七日，本公司根據首次公開發售後僱員持股計劃向5名 購股權承授人授予合共4,800,000份購股權以認購合共4,800,000股股份。 上述授出的概要載列如下： 授出日期： 二零二五年八月二十七日 購股權承授人數量： 5名（即1名董事及4名本 ...

Group 1 - The biotechnology sector in the Hong Kong stock market experienced a significant decline, with several companies reporting substantial drops in their stock prices [1] - Notable declines include Clover Biopharmaceuticals, which fell by 14.13%, and Beigene, which dropped by 8.33% [2] - Other companies such as Innovent Biologics and WuXi Biologics also saw declines exceeding 5%, indicating a broader trend of negative performance in the sector [1][2] Group 2 - The following companies reported specific percentage declines: Clover Biopharmaceuticals (-14.13%), Beigene (-8.33%), and Innovent Biologics (-6.50%) [2] - Additional companies with notable declines include Kintor Pharmaceutical (-6.38%), CanSino Biologics (-5.98%), and Zai Lab (-5.50%) [2] - The overall trend suggests a challenging environment for biotechnology stocks in the Hong Kong market [1]

Summary of Key Points Core Viewpoint - As of August 26, a total of 135 stocks reached their 52-week highs, indicating a strong market performance with notable leaders in the sector [1]. Stock Performance Highlights - The top three stocks with the highest increase rates are: - 恒基发展 (Hengji Development) at 69.72% with a closing price of 0.335 and a peak of 0.370 [1] - 中国智能交通 (China Intelligent Transportation) at 68.89% with a closing price of 0.305 and a peak of 0.380 [1] - 桦欣控股 (Hua Xin Holdings) at 54.26% with a closing price of 17.000, reaching its peak at the same price [1] Additional Notable Stocks - Other significant performers include: - 绿色经济 (Green Economy) at 22.16% [1] - 米兰站 (Milan Station) at 21.83% [1] - 永义国际 (Yongyi International) at 21.21% [1] - 金界控股 (Golden Realm Holdings) at 18.11% [1] 52-Week Low Rankings - The stocks that reached their 52-week lows include: - 鸿盛昌资源股权 (Hongsheng Chang Resources) at a low of 0.010, down 37.50% [4] - 德商产投服务 (DeShang Investment Services) at a low of 0.830, down 17.00% [4] - 新华联合投资 (Xinhua United Investment) at a low of 0.092, down 15.60% [4]

Group 1 - The core viewpoint of the article highlights the significant stock price increase of 基石药业-B (02616), which rose over 5% following a substantial investment by the Singapore government investment company (GIC) [1] - As of the latest report, the stock price reached 10.7 HKD with a trading volume of 301 million HKD [1] - GIC increased its holdings by acquiring 80.4 million shares at an average price of 7.9 HKD per share, totaling approximately 635 million HKD, raising its ownership from 0.00% to 5.49% [1] Group 2 - The company continues to implement strategic collaborations, with a new indication application for舒格利单抗 planned for submission to the European Medicines Agency (EMA) by March 2025 [1] - In January 2025, the company established a commercialization strategic partnership with SteinCares for 10 Latin American countries, and in July 2025, it partnered with Gentili for 23 countries in Western Europe and the UK [1] - The international influence of舒格利单抗 has expanded to over 60 countries globally [1]

Group 1 - The stock of Basilea Pharmaceutica (02616) has increased by over 5%, currently trading at 10.7 HKD with a transaction volume of 301 million HKD [1] - The Government of Singapore Investment Corporation (GIC) has increased its stake in Basilea by acquiring 80.4 million shares at an average price of 7.9 HKD per share, totaling approximately 635 million HKD, raising its ownership from 0.00% to 5.49% [1] - The company continues to implement strategic collaborations, with Shugli monoclonal antibody expected to submit a new indication application to the European Medicines Agency (EMA) by March 2025 for treating unresectable stage III NSCLC patients [1] Group 2 - In January 2025, the company reached a commercialization strategic cooperation agreement with SteinCares for 10 Latin American countries, and in July 2025, it established a strategic partnership with Gentili for 23 countries in Western Europe and the UK [1] - The international influence of Shugli monoclonal antibody has expanded to over 60 countries globally [1]